In Situ Hybridization ISH Market Size, Share, Growth Analysis, By Technology(Fluorescent In Situ Hybridization (FISH), Chromogenic In Situ Hybridization (CISH)), By Product(Instruments, Kits & Probes, Software, Service), By Application(Cancer, Cytogenetics, Developmental Biology, Infectious Diseases), By Region - Industry Forecast 2024-2031

In Situ Hybridization ISH Market Driver

• Over the past few years, there has been an increase in cancer cases worldwide. Recurrent genomic abnormalities have been identified as potential initiating factors for a number of cancers as a result of extensive research on human diseases over the past few decades. The integration of cytogenetic assays, such as ISH, with DNA FISH and IHC completes the set of in situ tools available to researchers for the creation, discovery, and application of next-generation diagnostic techniques. A special insight into the interaction between cancer cells and the tumour microenvironment while the cancer is progressing is provided by direct imaging of gene expression in situ at the RNA level. According to GLOBOCAN, there were 43.8 million cancer patients worldwide in 2018 and 9.6 million cancer-related deaths. In 2018, there were roughly 18.1 million new cases reported. By 2040, the number of cases of cancer could rise to 29.5 million, with a mortality rate of 16.5 million. Furthermore, compared to earlier estimates of 400,000, the incidence of haemophilia has tripled to reach 1,125,000, according to research from McMaster University (Canada). France, Canada, Italy, Australia, the UK, and New Zealand are the nation’s most severely impacted. The market will probably benefit from this increase.
• Increased use of the in-situ hybridization technique in research facilities and laboratories for conducting pharmacodynamics studies and diagnosing chromosomal abnormalities, infectious diseases, and cancer are factors driving growth. Other factors driving growth include rising healthcare spending, the high prevalence of chronic diseases, such as Alzheimer's disease and cancer.

In Situ Hybridization ISH Market Restraint

• Short-lived fluorophore molecules and difficulties in identifying individuals in samples with few copies of nucleic acids are two major factors anticipated to significantly slow market revenue growth. Since the signal's fluorescence rapidly decreases with passing time, FISH is a time-dependent detection method. Additionally, FISH is less sensitive for the detection of unbalanced translocations and is unable to detect low clonal cells for minimal residual disease following cancer treatment. In-situ hybridization's lower sensitivity compared to immunohistochemistry, the relatively low number of false-positive results, and sample contamination during PCR are some additional factors limiting market revenue growth. In-situ hybridization has become less popular as a commercial technique for diagnosing diseases with low titer loads of pathogens due to its high detection threshold.